Metraipolis › archive › dc_145af3d9fbec
Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with advanced pancreatic cancer refractory… — Europe PMC PMID:42371576
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42371576
- DOI
- 10.3389/fphar.2026.1805590
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-19T11:02:56.903Z
- SHA-256 of the archived text
7f2e8b0ba95006ebf4664a228f5d9aafa53ce5dd68a264b936825db4fb3044a8- Stable URL of this page
https://metraipolis.com/documento/dc_145af3d9fbec
How to cite
Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with advanced pancreatic cancer refractory… — Europe PMC PMID:42371576 — Europe PMC (en), https://europepmc.org/article/MED/42371576 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_145af3d9fbec (Metraipolis archive dc_145af3d9fbec, sha256 7f2e8b0ba95006ebf4664a228f5d9aafa53ce5dd68a264b936825db4fb3044a8)
BibTeX
@misc{dc145af3d9fbec,
title = {Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with advanced pancreatic cancer refractory… — Europe PMC PMID:42371576},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42371576},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_145af3d9fbec; sha256 7f2e8b0ba95006ebf4664a228f5d9aafa53ce5dd68a264b936825db4fb3044a8},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42371576. Agents can read the archived copy with the MCP tool read_document.